Puromycin

Puromycin

• CAS Number: 53-79-2
• UNSPSC Description: Puromycin dihydrochloride is the dihydrochloride salt of puromycin. Puromycin is an aminoglycoside antibiotic that inhibits protein synthesis.
• Target Antigen: Antibiotic; Bacterial; Parasite
• Type: Natural Products
• Related Pathways: Anti-infection
• Applications: COVID-19-immunoregulation
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/Puromycin.html
• Purity: 99.55
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : 1 mg/mL (ultrasonic)
• Smiles: OC[C@@H]1[C@@H](NC([C@@H](N)CC2=CC=C(OC)C=C2)=O)[C@H]([C@H](N3C=NC4=C3N=CN=C4N(C)C)O1)O
• Molecular Weight: 471.51
• References & Citations: [1]Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92.|[2]Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28(5):1176-82.|[3]Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6(4):275-7.Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Adv Funct Mater. 2019, 1808556.|Biochem Pharmacol. 2017 Mar 15;128:12-25.|Biol Direct. 2024 Nov 26;19(1):122.|bioRxiv. 2023 Jun 17.|bioRxiv. 2024 Sep 29:2024.09.26.615290.|Cancer Cell Int. 2019 Jul 24;19:192. |Cancer Immunol Res. 2023 May 2;CIR-22-0814.|Cell Signal. 2019 Mar 5;58:119-130. |Development. 2024 Sep 30:dev.202899.|Evid Based Complement Alternat Med. 2019 Mar 24;2019:1635837.|Hepatology. 2021 Apr;73(4):1327-1345.|Indian J Pharm Educ. 2024 Jun 21.|Int J Biol Sci. 2024 Oct 14;20(14):5548-5575.|Int J Oncol. 2020 Jul;57(1):161-170.|J Cell Mol Med. 2019 Feb;23(2):954-966.|J Exp Clin Cancer Res. 2016 Nov 7;35(1):173. |J Hepatocell Carcinoma. 2024 Sep 18:11:1763-1775.|J Transl Med. 2024 Nov 22;22(1):1052.|Mol Carcinog. 2024 Oct 10.|Onco Targets Ther. 2019 Jan 25;12:835-848. |Oncogene. 2024 Oct 7.|Placenta. 2024 Oct 21:158:156-164.|PLoS One. 2017 Oct 10;12(10):e0185565.|R Soc Open Sci. 2018 Aug 29;5(8):172376.|Res Sq. 2024 Nov 07.|Theranostics. 2020 May 16;10(14):6483-6499. |Theranostics. 2021 Mar 5;11(10):5045-5060.|Toxicol Appl Pharmacol. 2019 Sep 1;378:114625. |Transl Res. 2023 Apr 28;S1931-5244(23)00072-5.|Acta Pharmacol Sin. 2023 Feb 20.|Adv Mater. 2022 Oct 20;e2206793.|Adv Sci (Weinh). 2024 Feb 21:e2308531.|Adv Sci (Weinh). 2024 Jun 26:e2404822.|Adv Sci (Weinh). 2024 Oct 18:e2407967.|Aging. 2020 Sep 14;12(17):17122-17136.|Aging. 2021 Jun 8;13(11):14892-14909.|Am J Cancer Res. 2023 May 15;13(5):1718-1743.|Am J Cancer Res. 2023 Sep 15;13(9):4222-4234.|Am J Transl Res. 2021 Apr 15;13(4):2331-2349.|Am J Transl Res. 2021 May 15;13(5):4360-4375.|Anal Biochem. 2021 Aug 29;114357.|Antioxid Redox Signal. 2022 Jun 16.|Antioxidants (Basel). 2023 Aug 18;12(8):1634.|Arch Biochem Biophys. 2023 May 19;109642.|Autophagy. 2021 Mar 25;1-19.|Autophagy. 2024 Jul 26:1-17.|Bioact Mater. 12 November 2021.|Biochem Biophys Res Commun. 1 January 2022, Pages 34-41.|Biochem Biophys Res Commun. 2021 Oct 5;580:48-55.|Biochem Biophys Res Commun. 6 August 2022.|Biochem Pharmacol. 2020 Apr;174:113776.|Biochem Pharmacol. 2024 Jul 10:116418.|Biochem Pharmacol. 2024 Jul 10:116422.|Biochem Pharmacol. 2024 May 9:225:116256.|Biochim Biophys Acta Mol Basis Dis. 2024 Apr 20;1870(5):167195.|Biochim Biophys Acta Mol Basis Dis. 2024 Aug 5:167453.|Biochim Biophys Acta Mol Cell Res. 2024 Jun 3:119768.|Biodes Manuf. 03 March 2022.|Biodes Manuf. 2022 Apr 18.|Biol Res. 2024 May 17;57(1):30.|Biomed Pharmacother. 2020 Jan;121:109578.|bioRxiv. 2023 Mar 31.|bioRxiv. 2023 Oct 4.|bioRxiv. 2024 August 30.|bioRxiv. 2024 Mar 29.|bioRxiv. April 11, 2022.|BMC Cancer. 2018 Feb 13;18(1):182. |Bull Cancer. 2023 Feb 28;S0007-4551(23)00083-8.|Cancer Commun (Lond). 2022 Nov 9.|Cancer Immunol Res. 2023 Feb 22;CIR-22-0658.|Cancer Invest. 2021 Mar 8;1-34.|Cancer Lett. 2020 Nov 1;492:162-173.|Cancer Lett. 2021 Apr 29;S0304-3835(21)00180-4.|Cancer Lett. 2021 Jul 30;518:266-277.|Cancer Lett. 2024 Apr 9:591:216848.|Cancer Lett. 2024 Jan 25:216674.|Cancer Manag Res. 2021 Nov 30;13:8915-8928.|Cancer Med. 2019 Oct;8(13):5903-5915.|Cancer Res. 2023 Apr 16;CAN-22-3059.|Cancer Sci. 2024 Jun 26.|Cell Biol Toxicol. 2024 Aug 7;40(1):65.|Cell Commun Signal. 2022 Jun 15;20(1):87.|Cell Death Dis. 2020 Dec 2;11(12):1032.|Cell Death Dis. 2021 Oct 14;12(10):944.|Cell Death Dis. 2021 Sep 9;12(9):842.|Cell Death Dis. 2022 Apr 18;13(4):360.|Cell Death Dis. 2023 Feb 11;14(2):107.|Cell Death Dis. 2023 Nov 25;14(11):765.|Cell Death Dis. 2023 Oct 6;14(10):653.|Cell Death Dis. 2019 Nov 21;10(12):879. |Cell Death Discov. 2021 Aug 30;7(1):226.|Cell Death Discov. 2021 May 1;7(1):89.|Cell Death Discov. 2022 Apr 23;8(1):222.|Cell Death Discov. 2022 Dec 16;8(1):493.|Cell Death Discov. 2022 Feb 22;8(1):77.|Cell Death Discov. 2022 Oct 28;8(1):432.|Cell Mol Biol (Noisy-le-grand). 2024 Jun 5;70(6):122-128.|Cell Mol Immunol. 2024 Jun;21(6):546-560.|Cell Rep. 2024 Aug 22;43(9):114662.|Cell Rep. 2024 Dec 13;43(12):115060.|Cell Rep. 2024 Feb 27;43(2):113739.|Cell Rep. 2024 Mar 23;43(4):114003.|Cell Signal. 2020, 109878.|Clin Epigenetics. 2022 Dec 2;14(1):164.|Clin Transl Oncol. 2021 Apr 7.|Clin Transl Oncol. 2022 Dec 13.|Commun Biol. 2022 Aug 30;5(1):887.|Comput Biol Med. 2024 Feb, 169, 107975.|Dig Liver Dis. 2022 Dec 29;S1590-8658(22)00827-1.|Dis Markers. 2022 Sep 23;2022:8402116.|DNA Cell Biol. 2022 Apr;41(4):447-455.|EMBO Rep. 2021 Jun 23;e52205.|Environ Toxicol. 2023 Mar 15.|Environ Toxicol. 2023 Oct 4.|Exp Cell Res. 2023 Apr 11;427(1):113598.|Exp Cell Res. 2023 Apr 24;113613.|Exp Cell Res. 2024 Apr 16;438(1):114038.|Exp Mol Med. 2022 Jul;54(7):890-905.|Exp Mol Pathol. 2021 Oct 5;104704.|F1000Research. 03 Aug 2022.|Front Oncol. 21 April 2021.|Gene. 2024 Aug 22:931:148855.|Genes (Basel). 2022, 13(10), 1760.|Heliyon. 2022 Dec 6;8(12):e12118.|Heliyon. 2023 Aug 9.|Heliyon. 2023 Nov 15.|Int Immunopharmacol. 2023 Jul 15;122:110616.|Int J Biol Macromol. 2023 Apr 17;124476.|Int J Mol Sci. 2023 Sep 23, 24(19), 14476.|Int J Oncol. 2023 Apr;62(4):45.|Int J Oncol. 2024 Apr;64(4):45.|J Appl Toxicol. 2023 Apr 14.|J Biol Chem. 2021 Feb 10;296:100413.|J Biol Chem. 2021 Jan 8;100276.|J Biol Chem. 2023 Mar;299(3):102961.|J Cancer. 2023 May 8; 14(8): 1309-1320.|J Cancer. 2024 Sep 9;15(17):5762-5772.|J Cell Mol Med. 2023 Mar 14.|J Ethnopharmacol. 2023 Apr 3;116446.|J Exp Clin Cancer Res. 2021 Nov 25;40(1):373.|J Exp Clin Cancer Res. 2022 Mar 28;41(1):111.|J Exp Clin Cancer Res. 2023 Nov 6;42(1):294.|J Exp Clin Cancer Res. 2023 Oct 3;42(1):258.|J Hematol Oncol. 2021 Jul 10;14(1):109.|J Transl Med. 2024 Jun 20;22(1):584.|J Transl Med. 2024 May 21;22(1):485.|J Virol. 2024 Jun 28:e0083024.|Life Sci. 2022 Jan 19;293:120320.|Mbio. 2023 Oct 26:e0168823.|MedComm (2020). 2024 May 31;5(6):e576.|Mol Cancer. 2024 May 6;23(1):90.|Mol Cancer. 2019 Aug 22;18(1):127. |Mol Carcinog. 2023 Jun 28.|Mol Cell Biochem. 2021 Jun;476(6):2503-2512.|Mol Cell. 2023 Nov 20:S1097-2765(23)00914-0.|Mol Cell. 2023 Nov 24:S1097-2765(23)00911-5.|Mol Cell. 2024 Aug 1:S1097-2765(24)00593-8.|Mol Pharm. 2024 Jun 6.|Molecules. 2023, 28(3), 1103.|Nat Commun. 2019 Dec 2;10(1):5492. |Nat Commun. 2022 Mar 10;13(1):1248.|Neuro Oncol. 2022 Jun 20;noac156.|NPJ Precis Oncol. 2024 Mar 1;8(1):58.|Nucleic Acids Res. 2024 Jan 2:gkad1243.|Oncogene. 2021 Nov 29.|Oncogene. 2023 Aug 18.|Oncol Lett. 2023 Dec 18.|Oncol Rep. 2021 Feb;45(2):523-534.|Oncol Rep. 2023 Aug;50(2):148.|Oncotargets Ther. 2020 Sep 30;13:9701-9719.|Peer J Prints. June 6, 2022.|Phytomedicine. 2023 Mar 15;114:154769.|Poult Sci. 2023 Jul 14, 102864.|Reprod Biomed Online. 2023 Jun 23.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2021 Nov.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 Apr 17.|Research Square Preprint. 2023 Nov 25.|Research Square Preprint. 2023 Sep 27.|Research Square Print. 2022 Aug.|Research Square Print. 2023 Mar 15.|Sci China Life Sci. 2024 Sep 6.|Sci Rep. 2022 Nov 5;12(1):18809.|Science. 2024 Feb 2;383(6682):eadh4859.|Signal Transduct Target Ther. 2022 Feb 28;7(1):54.|Signal Transduct Target Ther. 2024 Dec 18;9(1):352.|SSRN. 2021 Jun.|STAR Protoc. 2022 Apr 13;3(2):101296.|STAR Protoc. 2022 Nov 2;3(4):101808.|Stem Cell Res Ther. 2024 Dec 2;15(1):458.|Stem Cell Rev Rep. 2023 Jan 11.|Stem Cells Int. 2020 Aug 29;2020:8860185. |Thorac Cancer. 2024 May 8.|Transl Oncol. 2024 Apr 24:45:101958.|Transl Oncol. 2024 Jul 3:47:101950.|Vet Microbiol. 2023 Jun 28;284:109823.|Virus Res. 2023 Apr 15;328:199086.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: Launched